Cromos Pharma, where the patients are

Global News

GSK, EMBL-EBI, Wellcome Trust form ‘big data’ research initiative

Friday, March 28, 2014 03:09 PM

A pioneering public-private research initiative between GlaxoSmithKline, the European Bioinformatics Institute (EMBL-EBI) and the Wellcome Trust Sanger Institute has formed to harness the power of “big data” and genome sequencing to improve the success rate for discovering new medicines. The new Center for Therapeutic Target Validation (CTTV) will aim to address a wide range of human diseases and will share its data openly in the interests of accelerating drug discovery.

More... »

CRF Health eCOA webinar series

Report: Drug developers drawn to orphan drugs market, create competitive pipelines

Friday, March 28, 2014 03:08 PM

New analysis from Frost & Sullivan's Product and Pipeline Assessment of the Global Orphan Drugs Market identifies rare cancers as the orphan therapeutic area with the highest level of drug development activity. Other disease areas witnessing considerable drug development activity include blood/lymphatic system diseases, infectious/parasitic diseases, neurological diseases, metabolic diseases and immunological/inflammatory diseases.

More... »


Oracle Health Sciences addresses need to analyze clinical trial genomic data

Friday, March 28, 2014 03:06 PM

Oracle Health Sciences has launched Oracle Health Sciences InForm Advanced Molecular Analytics. Integrated with Oracle Health Sciences InForm, the solution enables clinical trial managers to systematically and effectively collect, store and analyze genomic data captured in a clinical trial.

More... »

Numira appoints David Raminick V.P. of sales & marketing

Friday, March 28, 2014 01:14 PM

Numira, a CRO providing high resolution, 3D imaging services, visualization software and cloud computing for the life science market, has appointed David Raminick vice president of sales and marketing.

More... »

Mast Therapeutics initiates phase II study of MST-188 for acute limb ischemia

Friday, March 28, 2014 12:48 PM

Mast Therapeutics has initiated a phase II, clinical proof-of-concept study of MST-188 in combination with recombinant tissue plasminogen activator (rt-PA) in patients with acute lower limb ischemia.

More... »

Quintiles appoints Stella Blackburn to lead global risk management

Friday, March 28, 2014 12:33 PM

Quintiles has appointed Stella Blackburn, M.B. B.S., vice president and global head of Risk Management for its Real-World & Late Phase Research group. Blackburn will be responsible for leading the group’s risk management efforts in the U.S., E.U., Australia and Canada. Blackburn also will develop multidisciplinary risk management services, review and assist with interpretation of pharmacovigilance legislation and ensure compliance with regulations and best practices in the conduct of pharmacovigilance and risk management activities for the company’s real-world and late phase research efforts.

More... »

Precision for Medicine acquires Hobart Group Holdings

Wednesday, March 26, 2014 11:43 AM

Precision for Medicine, formed in 2012 to support next-generation approaches to drug development and commercialization, has acquired Hobart Group Holdings, a market access firm.

More... »

Spark Therapeutics, Genable Technologies collaborate

Wednesday, March 26, 2014 11:41 AM

Spark Therapeutics of Philadelphia and Genable Technologies, a privately held Dublin, Ireland-based biopharmaceutical company, are collaborating on Genable's lead therapeutic GT038, used to treat rhodopsin-linked autosomal dominant retinitis pigmentosa (RHO adRP). Genable will license certain adeno-associated virus (AAV) vector manufacturing patents from Spark. Spark will be the exclusive manufacturer of the product and provide development advice and experience to Genable to help in the ongoing development of GT038. Spark will receive milestone payments and royalties on future sales of GT038.

More... »

AstraZeneca completes purchase of Sumitomo Chemical’s stake in AstraZeneca K.K.

Wednesday, March 26, 2014 11:40 AM

AstraZeneca has completed the purchase of Sumitomo Chemical’s remaining shares in AstraZeneca K.K. The purchase was valued at approximately $102 million and gives AstraZeneca control of the entire shareholding of AstraZeneca K.K.

More... »

Orphan drug market expected to grow through 2018

Monday, March 24, 2014 02:51 PM

The returns on investment from orphan drugs are expected to help pharma companies overcome the impact of revenue loss due to expiry of patents of blockbuster drugs, according to ReportsnReports.com.

More... »

`
CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

April 14

Proposal calls for back-to-back trials to measure efficacy and effectiveness prior to FDA approval

Study: Minority populations under-represented in cancer trials, but have higher rates of incidence

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

Make way for mobile health in clinical trials
Despite patient retention, data quality benefits, regulatory hurdles persist

Global clinical trial laboratories decentralize
Regional labs reducing complexity, delivering cost and time savings

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Strategic alliances hit bumps in the road
Mixed relationship performance driving new approaches

Tapping community hospitals for clinical trial volunteers
New study finds high potential but infrastructure, resources are lacking

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs